Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Montelukast Sodium Market Growth Potential: How Will Market Size Shift Through 2030?
The montelukast sodium market size has experienced significant expansion in recent years. It is anticipated to grow from $4.2 billion in 2025 to $4.59 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. This historic period’s expansion can be attributed to several factors: the long-established clinical application of montelukast in controlling asthma, a rising prevalence of allergic respiratory diseases, its confirmed safety profile for long-term therapy, broad physician acceptance for maintenance treatment, and the availability of affordable generic alternatives.
The montelukast sodium market is anticipated to experience robust expansion over the coming years, reaching $6.33 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.4%. This projected growth is driven by factors such as the increasing worldwide prevalence of asthma and allergic rhinitis, a rise in pediatric asthma diagnoses, greater public understanding of non-steroidal treatments for asthma, wider availability of respiratory medications in developing regions, and ongoing preference for oral maintenance medications. Key trends during this period are expected to encompass an escalating need for leukotriene receptor antagonists in asthma care, the expanding application of montelukast for allergic rhinitis, the proliferation of generic montelukast sodium products, a clear preference for oral solid forms in long-term respiratory treatment, and a surge in prescriptions for both child and adult asthma sufferers.
Get A Free Sample Report With In-Depth Market Insights:
Montelukast Sodium Market Development Factors: What’s Supporting Demand?
The rising incidence of asthma is anticipated to drive expansion in the montelukast sodium market in the future. Asthma, a persistent respiratory ailment, is characterized by airway inflammation and narrowing, leading to recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing. The surge in asthma cases is attributed to factors such as environmental contamination, exposure to allergens, genetic factors, increased urbanization, evolving lifestyles, and respiratory illnesses. As a leukotriene receptor antagonist, montelukast sodium is administered for asthma to help avert and control its symptoms by inhibiting the activity of leukotrienes, substances that promote airway inflammation and constriction. An illustrative example comes from October 2024, where the National Asthma Council, an Australia-based non-profit organization, reported that in 2023, Australia experienced 474 asthma-related deaths, consisting of 325 females and 149 males. This number closely mirrors the 473 asthma-related deaths documented in 2022, indicating a stable pattern in asthma mortality across these two years. Consequently, the rising incidence of asthma is a key factor propelling the expansion of the montelukast sodium market.
Montelukast Sodium Market Segment Trends And Revenue Contributors
The montelukast sodium market covered in this report is segmented –
1) By Product: Crystal-like, Form-less Or Amorphous
2) By Dosage Form: Tablets, Oral Solutions
3) By Application: Bronchospasm, Allergic Coryza, Asthma, Urticaria, Other Applications
Subsegments:
1) By Crystal-Like: Monohydrate Crystal, Anhydrous Crystal, Spherical Crystals, Needle-Like Crystals, Polycrystalline Montelukast Sodium
2) By Form-Less Or Amorphous: Amorphous Powder, Amorphous Granules, Non-Crystalline Montelukast Sodium
Montelukast Sodium Market Transformation Trends: What Innovations Are Driving Change?
Companies operating in the montelukast sodium market are concentrating on creating innovative solutions, such as combination therapies, to offer more extensive allergy and asthma relief and enhance patient adherence. Combination therapies involve treatments that utilize two or more drugs together in a single regimen to address multiple disease pathways for improved efficacy. For instance, in October 2025, Cadila Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Dlorfast-M tablets, a fixed-dose combination therapy comprising desloratadine (5 mg) and montelukast (10 mg) for managing allergic rhinitis and urticaria. It provides comprehensive symptom control by acting on both histamine and leukotriene pathways through a convenient once-daily oral dosage. This advanced formulation aims to boost patient compliance and deliver lasting relief with good tolerability.
Montelukast Sodium Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the montelukast sodium market are Pfizer Inc., Merck & Co. Inc., Sanofi Aventis SA, Teva Pharmaceuticals USA Inc., Hetero Labs Ltd., Sun Pharma Industries Ltd., Aurobindo Pharma Limited, Cipla Inc., Intas Pharmaceuticals Ltd., Seqens Group, Sanyo Chemical Industries Ltd., Morepen Laboratories, Neuland Laboratories Ltd., Medopharm Private Ltd., BEC Chemicals Pvt. Ltd, Delmar Chemicals Inc., Kimia Biosciences Ltd., Ortin Laboratories Ltd., MSN Laboratories Pvt Ltd., Vamsi Labs Ltd., LGM Pharma LLC, HRV Global Life Sciences, Sigmak Lifesciences, Akums Lifesciences Ltd., Anwita Drugs & Chemicals Pvt Ltd
View The Full Montelukast Sodium Market Report:
Montelukast Sodium Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the montelukast sodium market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the montelukast sodium market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
